1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDihydroergotamine mesylateCat. No.: HY-B0670ACAS No.: 6190-39-2分式: CHNOS分量: 679.78作靶點: 5-HT Receptor作通路: GPCR/G Protein; Neuronal Signaling儲存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 month (protect fromligh

2、t)溶解性數(shù)據(jù)體外實驗 DMSO : 34 mg/mL (50.02 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.4711 mL 7.3553 mL 14.7106 mL5 mM 0.2942 mL 1.4711 mL 2.9421 mL10 mM 0.1471 mL 0.7355 mL 1.4711 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Dihyd

3、roergotamine甲磺酸鹽為麥物堿，可作于偏頭疼。REFERENCES1. Colman, I., et al., Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med,2005. 45(4): p. 393-401.2. Saper, J.R., et al., DHE in the pharmacotherapy of migraine: potential for a larger role. Headache, 2

4、006. 46 Suppl 4: p. S212-20.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. Schaerlinger, B., et al., Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance toantimigraine efficacy. Br J Pharmacol, 2003. 140(2): p. 277-84.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax: 0